An updated patent review of GLP-1 receptor agonists (2020-present)
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Type 2 diabetes (T2DM) and obesity present significant global health issues, requiring the development of long-lasting and highly effective pharmacotherapies. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) are commonly used for diabetes treatment, their potential for addressing obesity is still being explored. AREAS COVERED: This review offers a comprehensive overview of recently published patents from January 2020 to July 2023, focusing on modified GLP-1RAs, small molecule GLP-1RAs, GLP-1 R-based multi-agonists, GLP-1RA-based fusion proteins, and combination therapies. The patents discussed pertain to the treatment and prevention of diabetes and obesity. Patent searches were conducted using the PATENTSCOPE database of the World Intellectual Property Organization, using the keywords GLP-1, GLP-1/GIP, GLP-1/GCG, and GLP-1/GCG/GIP. EXPERT OPINION: In recent years, patents have emphasized two main goals for developing GLP-1RAs drugs: oral delivery and improved weight reduction effects. To address the growing demand for improved treatments, researchers have focused their efforts on developing GLP-1 R-based multi-agonists, orally administered GLP-1RAs, and combination therapies utilizing GLP-1RAs. These new approaches offer promising benefits, such as improved effectiveness by targeting multiple pathways and reduced side effects. Additionally, the development of new uses, oral forms, and long-lasting preparations will be crucial in shaping the future market potential of GLP-1 drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Moreover, the recently approved high-dose version of the once-weekly GLP-1RA semaglutide, available in a dosage of 2.4 mg (marketed as Wegovy), further elevates the average weight reduction to a range of 15–20% within this patient population [22].”
BackgroundInfluentialObesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 1×
“Obesity is a major contributor to global morbidity and mortality as it serves as a catalyst for numerous comorbidities including nonalcoholic fatty liver disease (NAFLD), type 2 diabetes (T2DM), cardiovascular disease, hypercholesterolemia, hypertension, and cancer [2–4].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Studies have shown that GIP also modulates glucagon secretion in a glucose-dependent manner, facilitating the clearance of lipids following a meal, and regulating food intake (Figure 3) [65].”
BackgroundGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“In this context, the appetite-suppressive effects of glucagon-like peptide-1 (GLP-1) and its analogues have proved valuable and are now approved for obesity treatment, having been in clinical use for T2DM for over a decade [7,8].”
BackgroundObesity and Severe Obesity Forecasts Through 2030
Finkelstein, E. A., Khavjou, O. A., Thompson, H., Trogdon, J. G., Pan, L., Sherry, B., & Dietz, W. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.10.026 · Cited by 1,418
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Furthermore, GLP-1 hinders gastric emptying, induces feelings of satiety, and ultimately leads to a decrease in body weight [9].”
BackgroundAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 4×
“…to bridge this divide, researchers have explored the concept of the ‘co-agonist’ strategy, which involves blending GLP-1 with other hormones from the proglucagon family, as well as related peptides such as glucagon, glucose-dependent insulinotropic polypeptide (GIP) and amylin analogues [28–30].”
BackgroundInfluentialThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“The half-life of tirzepatide is extended to 116.7 hours by further modification, which involves elongation of the C-terminus with a sequence derived from exenatide and conjugation of a fatty acid side chain [68].”
BackgroundInfluentialBariatric Surgery and Long-term Durability of Weight Loss
Maciejewski, M. L., Arterburn, D. E., Van Scoyoc, L., Smith, V. A., Yancy, W. S., Weidenbacher, H. J., Livingston, E. H., & Olsen, M. K. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2016.2317 · Cited by 720
Conformational complexity of G-protein-coupled receptors
Kobilka, B. K., & Deupi, X. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.003 · Cited by 694
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426 · cited 1×
“…for patients with diabetes, exhibiting beneficial effects such as improved insulin sensitivity, blood glucose control, weight reduction, decreased levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides, and increased levels of high-density lipoprotein cholesterol (HDL-C) [128,129].”
BackgroundGlucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406 · cited 1×
“In this context, the appetite-suppressive effects of glucagon-like peptide-1 (GLP-1) and its analogues have proved valuable and are now approved for obesity treatment, having been in clinical use for T2DM for over a decade [7,8].”
BackgroundBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“However, the effectiveness of GLP-1RAs as standalone therapies is hindered by the occurrence of dose-dependent gastrointestinal adverse events [23,24].”
BackgroundEnebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316 · cited 1×
“Additionally, some studies are investigating the potential of combination therapies involving GLP-1RAs and other drugs, such as the combination of semaglutide and the long-acting amylin analogue cagrilintide, for the treatment of both T2DM and obesity [33,34].”
BackgroundLiraglutide for weight management: a critical review of the evidence
Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311
Farr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268
Grönroos, S., Helmiö, M., Juuti, A., Tiusanen, R., Hurme, S., Löyttyniemi, E., Ovaska, J., Leivonen, M., Peromaa-Haavisto, P., Mäklin, S., et al. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2020.5666 · Cited by 216
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192
TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator
Tsai, V. W.-W., Macia, L., Johnen, H., Kuffner, T., Manadhar, R., Jørgensen, S. B., Lee-Ng, K. K. M., Zhang, H. P., Wu, L., Marquis, C. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055174 · Cited by 188 · cited 1×
“Growth differentiation factor-15 (GDF15) possesses the ability to induce weight loss by inhibiting dietary intake through its specific binding to RET (ret proto-oncogene) and GFRAL (GDNF family receptor alpha-like) receptors, which are predominantly expressed in brain tissue [134].”
BackgroundFrías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00174-1 · Cited by 188 · cited 1×
“Nevertheless, it appears that the maximal efficacy of GLP-1RAs may reach a plateau with higher doses, particularly in patients with diabetes [25].”
BackgroundAnti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182
Bossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179 · cited 1×
“SAR441255, a GLP-1 R/GCGR/GIPR triple agonist developed by Sanofi, offers enhanced therapeutic benefits [100], and several other GLP-1 R/GCGR/GIPR triple agonists, including HM15211 (Hanmi Pharmaceutical) and NN9423 (Novo Nordisk), are currently undergoing clinical trials [30].”
BackgroundSaxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01391-w · Cited by 156
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152 · cited 1×
“Notably, these agonists stand as the sole class of pharmaceuticals that have received approval for both indications [10,11].”
BackgroundZimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149 · cited 1×
“Among these, dual agonists targeting both GLP-1 R and GCGR, such as BI 456,906 and pemvidutide, have shown promising results in terms of weight loss, surpassing the effects of GLP-1 R mono-agonists [95,96].”
BackgroundThe advantages and disadvantages of sleeve gastrectomy; clinical laboratory to bedside review
Kheirvari, M., Nikroo, N. D., Jaafarinejad, H., Farsimadan, M., Eshghjoo, S., Hosseini, S., & Anbara, T. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03496 · Cited by 143
Gastrointestinal hormones and regulation of gastric emptying
Camilleri, M. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000448 · Cited by 140
Glucagon‐like Peptide‐2 and the Regulation of Intestinal Growth and Function
Brubaker, P. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170055 · Cited by 137
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
Development of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00565 · Cited by 129
Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123
Madsen, M. S. A., Holm, J. B., Pallejà, A., Wismann, P., Fabricius, K., Rigbolt, K., Mikkelsen, M., Sommer, M., Jelsing, J., Nielsen, H. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52103-x · Cited by 121
Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids
Alhabeeb, H., AlFaiz, A., Kutbi, E., AlShahrani, D., Alsuhail, A., AlRajhi, S., Alotaibi, N., Alotaibi, K., AlAmri, S., Alghamdi, S., et al. (2021) · Nutrients · doi:10.3390/nu13020481 · Cited by 106
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Kharitonenkov, A., & DiMarchi, R. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 100
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 95
Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O’Brien, S., Collinson, A., Papworth, M. A., Fredin, M. F., Jermutus, L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426288 · Cited by 87
Ji, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., Cai, C., Deng, H., Feng, L., Song, B., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101691 · Cited by 83
Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81 · cited 1×
“The COVID-19 pandemic has brought attention to the significant correlation between obesity and adverse outcomes [5].”
BackgroundBhat, V. K., Kerr, B. D., Flatt, P. R., & Gault, V. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.009 · Cited by 77
A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome
Kim, E. R., Park, J. S., Kim, J. H., Oh, J. Y., Oh, I. J., Choi, D. H., Lee, Y. S., Park, I. S., Kim, S., Lee, D. H., et al. (2022) · Hepatology · doi:10.1002/hep.32235 · Cited by 77
Bhat, V. K., Kerr, B. D., Vasu, S., Flatt, P. R., & Gault, V. A. (2013) · Diabetologia · doi:10.1007/s00125-013-2892-2 · Cited by 67
Teduglutide: A Review in Short Bowel Syndrome
Kim, E., & Keam, S. J. (2017) · Drugs · doi:10.1007/s40265-017-0703-7 · Cited by 65
Pratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15184 · Cited by 62
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 60
Glucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive Physiology · doi:10.1002/cphy.c200013 · Cited by 59
The importance of GLP‐1 and PYY in resistant starch's effect on body fat in mice
Zhou, J., Martin, R. J., Raggio, A. M., Shen, L., McCutcheon, K., & Keenan, M. J. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400904 · Cited by 57
Fiorentino, T. V., Casiraghi, F., Davalli, A. M., Finzi, G., La Rosa, S., Higgins, P. B., Abrahamian, G. A., Marando, A., Sessa, F., Perego, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.93091 · Cited by 51
Jiang, H., Pang, S., Zhang, Y., Yu, T., Liu, M., Deng, H., Li, L., Feng, L., Song, B., Han-Zhang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31328-x · Cited by 50
Su, H., He, M., Li, H., Liu, Q., Wang, J., Wang, Y., Gao, W., Zhou, L., Liao, J., Young, A. A., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002892 · Cited by 47
Reiner, J., Berlin, P., Held, J., Thiery, J., Skarbaliene, J., Griffin, J., Russell, W., Eriksson, P., Berner‐Hansen, M., Ehlers, L., et al. (2022) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2286 · Cited by 43
Coveleskie, K., Kilpatrick, L. A., Gupta, A., Stains, J., Connolly, L., Labus, J. S., Sanmiguel, C., & Mayer, E. A. (2017) · Obesity Science & Practice · doi:10.1002/osp4.124 · Cited by 40
Selective hydrogenation catalyst, preparation method and application thereof
(2021) · Focus on Catalysts · doi:10.1016/j.focat.2021.10.033 · Cited by 39
Cagrilintide plus semaglutide for obesity management
Becerril, S., & Frühbeck, G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00944-2 · Cited by 38
Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure
Sforza, A., Vigorelli, V., Rurali, E., Perrucci, G. L., Gambini, E., Arici, M., Metallo, A., Rinaldi, R., Fiorina, P., Barbuti, A., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01486-9 · Cited by 37
GLP-1R agonists for the treatment of obesity: a patent review (2015-present)
Liu, C., Zou, Y., & Qian, H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1811851 · Cited by 28
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions
Sigalet, D. L. (2018) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2018.07.008 · Cited by 24
Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
Seino, Y., & Yamazaki, Y. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13816 · Cited by 22
KLEIN, S., NESTOR, J. J., HARRIS, M. S., SUYUNDIKOV, A., CASPER, R., STEELE, S. M., PAYNE, J. D., KRISHNAN, V., ROBERTS, M. S., & BROWNE, S. K. (2022) · Diabetes · doi:10.2337/db22-334-or · Cited by 21
Bain, E. K., & Bain, S. C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 20
Morieri, M. L., Raz, I., Consoli, A., Rigato, M., Lapolla, A., Broglio, F., Bonora, E., Avogaro, A., Fadini, G. P., for the DARWIN-FUP network, et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-02002-2 · Cited by 6
Research works printed but not linked: 6
- Hanmi Pharm. Co., Ltd. Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof. WO2020263063. 2020.
- Shenzhen Deeply-invasive Biopharmaceutical Co., Ltd. GLP-1R/GCGR/GIPR triple receptor agonist and application thereof. CN114437181A. 2022.
- The United Bio-technology (Hengqin) Co., Ltd. Multi-agonist and use thereof. WO2022247701. 2022.
- Jiangsu Chinese New Medicine Co., Ltd. GLP-1, GIP and GCG multiple receptor agonist proteins. CN114621327A. 2022.
- Heptares Therapeutics Limited. Oral GLP receptor agonists. WO2021186169. 2021.
- Janssen Pharmaceutica. Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof. CN112004822A. 2020.
Cited by
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
Guo, H., Yang, J., Huang, J., Xu, L., Lv, Y., Wang, Y., Ren, J., Feng, Y., Zheng, Q., & Li, L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100162 · Cited by 32
“Clinical trials for GLP-1/GIP/GCG triple agonists are ongoing [19].”
Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights
Padmanaban, S., Baek, J.-W., Sahithya, C. S., Saipriya, C., Samrot, A. V., Gosu, V., Park, I., Radhakrishnan, K., & Kim, D. (2025) · Liver Research · doi:10.1016/j.livres.2025.04.002 · Cited by 22
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
Self-citation
Metadata
- Authors
- Lu, W., Zhou, Z., Jiang, N., & Han, J.
- Affiliations
- Guangxi Medical University (CN)
- Youjiang Medical College for Nationalities (CN)
- Jiangsu Normal University (CN)
- Corresponding author
- Zhou, Zhongbo
- Jiang, Neng
- Han, Jing
- ORCID
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2023-09-02
- Volume
- 33
- Issue
- 9
- Pages
- 597-612
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W4387866199
- Cited by
- 17
- References
- 72
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 4
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Patents (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Guangxi Science Fund for Distinguished Young Scholars (2022GXNSFFA035030)
- Special Funds for Science and Technology Development under the Guidance of the Central Government (ZY20198020)
- National Natural Science Foundation of China (82173663)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, GIP/GLP-1 receptor agonist, combination therapy, sustained drug release, weight loss, pharmaceutical patents
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Patents as Topic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.